BRICKELL BIOTECH, INC.

(BBI)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
4.070 USD   +7.96%
08/02Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
AQ
07/29BRICKELL BIOTECH, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
07/29Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

08/02/2022 | 04:06pm EDT

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.

To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conference ID number: 10168280. To access the live audio webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website for approximately 90 days.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Brickell’s pipeline consists of several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm® and Pluvicto®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that Brickell believes can meaningfully benefit patients who are suffering from chronic, debilitating diseases that are underserved by available therapies. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com


Primary Logo

Source: Brickell Biotech, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about BRICKELL BIOTECH, INC.
08/02Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporat..
AQ
07/29BRICKELL BIOTECH, INC. : Change in Directors or Principal Officers, Amendments to Articles..
AQ
07/29Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Dire..
CI
07/20Brickell Biotech Regains Compliance With Nasdaq's Minimum Bid Price Requirement for Con..
MT
07/20BRICKELL BIOTECH : Regains Compliance with Nasdaq Minimum Bid Price Requirement - Form 8-K
PU
07/20BRICKELL BIOTECH, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/20Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
07/06Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
AQ
07/05BRICKELL BIOTECH : Announces 1-For-45 Reverse Stock Split - Form 8-K
PU
07/05BRICKELL BIOTECH, INC. : Material Modification to Rights of Security Holders, Amendments t..
AQ
More news
Analyst Recommendations on BRICKELL BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2022 4,72 M - -
Net income 2022 -23,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,48x
Yield 2022 -
Capitalization 10,8 M 10,8 M -
Capi. / Sales 2022 2,29x
Capi. / Sales 2023 2,88x
Nbr of Employees 16
Free-Float 98,7%
Chart BRICKELL BIOTECH, INC.
Duration : Period :
Brickell Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRICKELL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,07 $
Average target price 39,56 $
Spread / Average Target 872%
EPS Revisions
Managers and Directors
Robert B. Brown Chief Executive Officer & Director
Albert N. Marchio Chief Financial & Accounting Officer
Reginald L. Hardy Chairman
Deepak Chadha Chief Research & Development Officer
Nancy Seretta Head-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
BRICKELL BIOTECH, INC.-63.40%10
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093